The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


ZINPLAVA (Formely known Bezlotoxumab MSD))



Merck Sharp & Dohme BVEU/1/16/1156/001

Main Information

Trade NameZINPLAVA (Formely known Bezlotoxumab MSD))
Active SubstancesBezlotoxumab
Dosage FormConcentrate for solution for infusion
Licence HolderMerck Sharp & Dohme BV
Licence NumberEU/1/16/1156/001

Group Information

ATC CodeJ06BB Specific immunoglobulins
J06BB21 Bexlooxumab

Status

License statusAuthorised
Licence Issued18/01/2017
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back